Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System

Stephen B. Williams(Cedars-Sinai Medical Center), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), John F. Ward(The University of Texas MD Anderson Cancer Center), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), Surena F. Matin(The University of Texas MD Anderson Cancer Center), Xuemei Wang(The University of Texas MD Anderson Cancer Center), John W. Davis(The University of Texas MD Anderson Cancer Center), Amado Zurita‐Saavedra(The University of Texas MD Anderson Cancer Center), Mary Achim(The University of Texas MD Anderson Cancer Center), Louis L. Pisters(The University of Texas MD Anderson Cancer Center)
Clinical Genitourinary Cancer
October 26, 2015
10.1016/j.clgc.2015.10.008
Cited by 18

Related Papers

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|516
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502